OBJECTIVE: An inflammatory response after cardiac surgery is associated with worse clinical outcomes, but recent trials to attenuate it have been neutral. We evaluated the association between systemic inflammatory response syndrome (SIRS) and mortality after transcatheter (TAVR) and surgical aortic valve replacement (SAVR) for aortic stenosis (AS) and evaluated whether diabetes influenced this relationship. METHODS: Patients (n=747) with severe AS treated with TAVR (n=264) or SAVR (n=483) between January 2008 and December 2013 were included and 37% had diabetes mellitus. SIRS was defined by four criteria 12-48 h after aortic valve replacement (AVR): (1) white blood cell count <4 or >12; (2) heart rate >90; (3) temperature <36 or >38°C; or (4) respiratory rate >20. Severe SIRS was defined as meeting all four criteria. The primary endpoint was 6-month all-cause mortality (60 deaths occurred by 6 months). Inverse probability weighting (IPW) was performed on 44 baseline and procedural variables to minimise confounding. RESULTS: Severe SIRS developed in 6% of TAVR patients and 11% of SAVR patients (p=0.02). Six-month mortality tended to be higher in those with severe SIRS (15.5%) versus those without (7.4%) (p=0.07). After adjustment, severe SIRS was associated with higher 6-month mortality (IPW adjusted HR 2.77, 95% CI 2.04 to 3.76, p<0.001). Moreover, severe SIRS was more strongly associated with increased mortality in diabetic (IPW adjusted HR 4.12, 95% CI 2.69 to 6.31, p<0.001) than non-diabetic patients (IPW adjusted HR 1.74, 95% CI 1.10 to 2.73, p=0.02) (interaction p=0.007). The adverse effect of severe SIRS on mortality was similar after TAVR and SAVR. CONCLUSIONS: Severe SIRS was associated with a higher mortality after SAVR or TAVR. It occurred more commonly after SAVR and had a greater effect on mortality in diabetic patients. These findings may have implications for treatment decisions in patients with AS, may help explain differences in outcomes between different AVR approaches and identify diabetic patients as a high-risk subgroup to target in clinical trials with therapies to attenuate SIRS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: An inflammatory response after cardiac surgery is associated with worse clinical outcomes, but recent trials to attenuate it have been neutral. We evaluated the association between systemic inflammatory response syndrome (SIRS) and mortality after transcatheter (TAVR) and surgical aortic valve replacement (SAVR) for aortic stenosis (AS) and evaluated whether diabetes influenced this relationship. METHODS:Patients (n=747) with severe AS treated with TAVR (n=264) or SAVR (n=483) between January 2008 and December 2013 were included and 37% had diabetes mellitus. SIRS was defined by four criteria 12-48 h after aortic valve replacement (AVR): (1) white blood cell count <4 or >12; (2) heart rate >90; (3) temperature <36 or >38°C; or (4) respiratory rate >20. Severe SIRS was defined as meeting all four criteria. The primary endpoint was 6-month all-cause mortality (60 deaths occurred by 6 months). Inverse probability weighting (IPW) was performed on 44 baseline and procedural variables to minimise confounding. RESULTS: Severe SIRS developed in 6% of TAVR patients and 11% of SAVR patients (p=0.02). Six-month mortality tended to be higher in those with severe SIRS (15.5%) versus those without (7.4%) (p=0.07). After adjustment, severe SIRS was associated with higher 6-month mortality (IPW adjusted HR 2.77, 95% CI 2.04 to 3.76, p<0.001). Moreover, severe SIRS was more strongly associated with increased mortality in diabetic (IPW adjusted HR 4.12, 95% CI 2.69 to 6.31, p<0.001) than non-diabeticpatients (IPW adjusted HR 1.74, 95% CI 1.10 to 2.73, p=0.02) (interaction p=0.007). The adverse effect of severe SIRS on mortality was similar after TAVR and SAVR. CONCLUSIONS: Severe SIRS was associated with a higher mortality after SAVR or TAVR. It occurred more commonly after SAVR and had a greater effect on mortality in diabeticpatients. These findings may have implications for treatment decisions in patients with AS, may help explain differences in outcomes between different AVR approaches and identify diabeticpatients as a high-risk subgroup to target in clinical trials with therapies to attenuate SIRS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Michael E Halkos; Patrick Kilgo; Omar M Lattouf; John D Puskas; William A Cooper; Robert A Guyton; Vinod H Thourani Journal: Ann Thorac Surg Date: 2010-07 Impact factor: 4.330
Authors: Vasilis Babaliaros; Chandan Devireddy; Stamatios Lerakis; Robert Leonardi; Sebastian A Iturra; Kreton Mavromatis; Bradley G Leshnower; Robert A Guyton; Mihir Kanitkar; Patricia Keegan; Amy Simone; James P Stewart; Nima Ghasemzadeh; Peter Block; Vinod H Thourani Journal: JACC Cardiovasc Interv Date: 2014-07-30 Impact factor: 11.195
Authors: Jan M Dieleman; Arno P Nierich; Peter M Rosseel; Joost M van der Maaten; Jan Hofland; Jan C Diephuis; Ronald M Schepp; Christa Boer; Karel G Moons; Lex A van Herwerden; Jan G Tijssen; Sandra C Numan; Cor J Kalkman; Diederik van Dijk Journal: JAMA Date: 2012-11-07 Impact factor: 56.272
Authors: Enzo Lüsebrink; Antonia Kellnar; Clemens Scherer; Kathrin Krieg; Mathias Orban; Tobias Petzold; Sven Peterss; Stefan Kääb; Stefan Brunner; Daniel Braun; Christian Hagl; Jörg Hausleiter; Steffen Massberg; Martin Orban Journal: Clin Res Cardiol Date: 2021-05-09 Impact factor: 5.460
Authors: Jedrzej Hoffmann; Silvia Mas-Peiro; Alexander Berkowitsch; Felicitas Boeckling; Tina Rasper; Konrad Pieszko; Roberta De Rosa; Jarosław Hiczkiewicz; Paweł Burchardt; Stephan Fichtlscherer; Andreas M Zeiher; Stefanie Dimmeler; Mariuca Vasa Nicotera Journal: ESC Heart Fail Date: 2020-07-08
Authors: Ayman Elbadawi; Ahmed H Mohamed; Islam Y Elgendy; Gbolahan O Ogunbayo; Michael Megaly; Hend I Shahin; Karim Mahmoud; Mohamed A Omer; Ahmed Abuzaid; Ken Fujise; Syed Gilani Journal: Cardiol Ther Date: 2019-11-11
Authors: Haitham Abu Khadija; Gera Gandelman; Omar Ayyad; Mustafa Jaber; Lion Poles; Michael Jonas; Offir Paz; Firas Abu Sbaih; Gal Sella; Sara Shimoni; Jacob George; Alex Blatt Journal: PLoS One Date: 2021-10-26 Impact factor: 3.240